All > Montreal > Hepatocellular Carcinoma

Neoadjuvant for Liver Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Liver Cancer+1 MoreNeoadjuvant - CombinationProduct
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing two different treatments for people with a certain type of liver cancer. The first group of people will get a drug called Atezolizumab, and the second group will get a different drug called Bevacizumab. The trial will compare how well each treatment works.

Eligible Conditions
  • Liver Cancer
  • Portal Vein Tumour Thrombosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
study treatment plan
1
Stereotactic Body Radiation Therapy
1
Yttrium-90 (Y-90) resin microspheres

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: 2 years

17 Weeks
Hepatectomy
2 years
Response rate
Survival
Survival Progression Free
Toxicity to Atezolizumab/Bevacizumab
Toxicity to SBRT
90 days post operatively
Postoperative complications

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
study treatment plan
1
Stereotactic Body Radiation Therapy
1
Yttrium-90 (Y-90) resin microspheres

Trial Design

2 Treatment Groups

Neoadjuvant Atezolizumab/Bevacizumab
1 of 2
Neoadjuvant SBRT
1 of 2

Experimental Treatment

70 Total Participants · 2 Treatment Groups

Primary Treatment: Neoadjuvant · No Placebo Group · Phase 2

Neoadjuvant Atezolizumab/Bevacizumab
CombinationProduct
Experimental Group · 1 Intervention: Neoadjuvant · Intervention Types: CombinationProduct
Neoadjuvant SBRT
CombinationProduct
Experimental Group · 1 Intervention: Neoadjuvant · Intervention Types: CombinationProduct

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Hoffmann-La RocheIndustry Sponsor
2,360 Previous Clinical Trials
1,067,571 Total Patients Enrolled
4 Trials studying Liver Cancer
156 Patients Enrolled for Liver Cancer
Ontario Clinical Oncology Group (OCOG)Lead Sponsor
60 Previous Clinical Trials
20,593 Total Patients Enrolled
Jim Wright, MDStudy DirectorOCOG Director
3 Previous Clinical Trials
220 Total Patients Enrolled
Brandon Meyers, MDPrincipal Investigatorprinciple investigator

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
A lesion measuring 10 cm or less in maximum diameter on computed tomography (CT) or magnetic resonance imaging (MRI) is considered small.
Patients with Child-Pugh Class A cirrhosis, within 14 days prior to randomization, without any transfusions within 3 months, were included in the study.
, can often be successfully resected Solitary HCC without biliary invasion, or metastases, that has been proven through a biopsy can often be successfully resected.
PVTT involving the portal vein branches refers to a condition in which cancerous tumors develop in the branches of the portal vein
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top